Logo image of ANCN

Anchiano Therapeutics Ltd ADR (ANCN) Stock Price, Quote, News and Overview

NASDAQ:ANCN - Nasdaq -

4.71  +0.24 (+5.37%)

After market: 5.53 +0.82 (+17.41%)

ANCN Quote, Performance and Key Statistics

Anchiano Therapeutics Ltd ADR

NASDAQ:ANCN (3/16/2021, 8:00:01 PM)

After market: 5.53 +0.82 (+17.41%)

4.71

+0.24 (+5.37%)

Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
Statistics
52 Week High10.55
52 Week Low0.56
Market Cap34.95M
Shares7.42M
Float6.97M
Yearly DividendN/A
Dividend YieldN/A
PE6.04
Fwd PEN/A
Earnings (Next)03-08 2022-03-08/bmo
IPON/A N/A


ANCN short term performance overview.The bars show the price performance of ANCN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 100 200 300

ANCN long term performance overview.The bars show the price performance of ANCN in the last 1, 2 and 3 years. 1 year 2 years 3 years 200 400 600

The current stock price of ANCN is 4.71 null. In the past month the price decreased by -3.68%. In the past year, price increased by 640.57%.

Anchiano Therapeutics Ltd ADR / ANCN Daily stock chart

About ANCN

Company Profile

Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company. It focuses on the discovery and development of novel therapies to treat cancer. The company's product candidate, inodiftagene vixteplasmid, is in development as a treatment for non-muscle-invasive bladder cancer. It operates primarily in Cambridge, MA and Jerusalem, Israel. Anchiano Therapeutics Ltd. is based in CAMBRIDGE.

Company Info

Anchiano Therapeutics Ltd ADR

ONE KENDALL SQUARE BUILDING 400 SUITE 14-105

JERUSALEM L3 9777401

CEO: Dr. Frank Haluska

Phone: 857-259-4622

Anchiano Therapeutics Ltd ADR / ANCN FAQ

What is the stock price of Anchiano Therapeutics Ltd ADR today?

The current stock price of ANCN is 4.71 null. The price increased by 5.37% in the last trading session.


What is the ticker symbol for Anchiano Therapeutics Ltd ADR stock?

The exchange symbol of Anchiano Therapeutics Ltd ADR is ANCN and it is listed on the Nasdaq exchange.


On which exchange is ANCN stock listed?

ANCN stock is listed on the Nasdaq exchange.


What is Anchiano Therapeutics Ltd ADR worth?

Anchiano Therapeutics Ltd ADR (ANCN) has a market capitalization of 34.95M null. This makes ANCN a Nano Cap stock.


What are the support and resistance levels for Anchiano Therapeutics Ltd ADR (ANCN) stock?

Anchiano Therapeutics Ltd ADR (ANCN) has a support level at 3.08 and a resistance level at 4.72. Check the full technical report for a detailed analysis of ANCN support and resistance levels.


Should I buy Anchiano Therapeutics Ltd ADR (ANCN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does Anchiano Therapeutics Ltd ADR (ANCN) stock pay dividends?

ANCN does not pay a dividend.


When does Anchiano Therapeutics Ltd ADR (ANCN) report earnings?

Anchiano Therapeutics Ltd ADR (ANCN) will report earnings on 2022-03-08, before the market open.


What is the Price/Earnings (PE) ratio of Anchiano Therapeutics Ltd ADR (ANCN)?

The PE ratio for Anchiano Therapeutics Ltd ADR (ANCN) is 6.04. This is based on the reported non-GAAP earnings per share of 0.78 and the current share price of 4.71 null. Check the full fundamental report for a full analysis of the valuation metrics for ANCN.


ANCN Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to ANCN. When comparing the yearly performance of all stocks, ANCN is one of the better performing stocks in the market, outperforming 98.01% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ANCN Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ANCN. ANCN may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ANCN Financial Highlights

Over the last trailing twelve months ANCN reported a non-GAAP Earnings per Share(EPS) of 0.78. The EPS increased by 34.1% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -187.88%
ROE N/A
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%84.51%
Sales Q2Q%N/A
EPS 1Y (TTM)34.1%
Revenue 1Y (TTM)N/A

ANCN Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 60% to ANCN. The Buy consensus is the average rating of analysts ratings from 1 analysts.


Ownership
Inst Owners0.06%
Ins Owners93.99%
Short Float %N/A
Short RatioN/A
Analysts
Analysts60
Price TargetN/A
EPS Next Y-736.99%
Revenue Next YearN/A